SCHEMBL1968464

SCHEMBL1968464

COC(=O)C(C)c1ccc(OC(C)=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
HPGD P15428 1/20 0.50
ELANE P08246 3/20 0.49
PTGS2 P35354 2/20 0.46
PTGS1 P23219 1/20 0.46
MAPT P10636 3/20 0.46
ALDH1A1 P00352 1/20 0.46
HSP90AA1 P07900 1/20 0.46
GAA P10253 1/20 0.46
POLB P06746 1/20 0.46
PKM P14618 1/20 0.46
KDM4E B2RXH2 2/20 0.45
CYP3A4 P08684 2/20 0.45
ABCB11 O95342 1/20 0.45
ESR1 P03372 1/20 0.45
ADRA2A P08913 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
PDE4A P27815 1/20 0.45
ADRA1A P35348 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30342652 0.89 ELANE (0.58) HPGDELANEPTGS2PTGS1ALDH1A1
SCHEMBL11460444 0.85 TDP1 (0.58) LMNAPTGS2PTGS1MAPTCYP2C9
SCHEMBL4007061 0.83 MEN1 (0.54) HPGDPTGS2PTGS1MAPTCYP3A4
SCHEMBL9838246 0.83 LMNA (0.52) LMNAELANEPTGS2MAPTPOLB
SCHEMBL14402158 0.81 HPGD (0.49) HPGDPTGS2PTGS1MAPTCYP3A4
SCHEMBL1968508 0.81 LMNA (0.53) LMNAELANEPTGS2PTGS1MAPT
SCHEMBL12583789 0.81 LMNA (0.48) LMNAELANEMAPTALDH1A1HSP90AA1
SCHEMBL1969461 0.81 LMNA (0.48) LMNAELANEMAPTALDH1A1HSP90AA1
SCHEMBL8195056 0.81 CYP2C19 (0.62) LMNAHPGDPTGS2PTGS1MAPT
SCHEMBL10995771 0.80 LMNA (0.44) LMNAELANEPTGS2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168667-B2 Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such GALAPAGOS NV (BE) 2012-05-01 US disclosed
US-8168667-B2 Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such GALAPAGOS NV (BE) 2012-05-01 US disclosed
US-8168667-B2 Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such GALAPAGOS NV (BE) 2012-05-01 US disclosed
EP-2026799-B1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH GALAPAGOS SAS (FR) 2011-06-22 EP disclosed
EP-2026799-B1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH GALAPAGOS SAS (FR) 2011-06-22 EP disclosed
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH DART THERAPUTICS, LLC. 2010-08-19 US disclosed
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH DART THERAPUTICS, LLC. 2010-08-19 US disclosed
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH DART THERAPUTICS, LLC. 2010-08-19 US disclosed
US-20100063120-A1 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such SASU, GALAPAGOS (FR) 2010-03-11 US disclosed
US-20100063120-A1 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such SASU, GALAPAGOS (FR) 2010-03-11 US disclosed
US-20100063120-A1 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such SASU, GALAPAGOS (FR) 2010-03-11 US disclosed
EP-2026799-A2 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH Galapagos SAS (FR) 2009-02-25 EP disclosed
WO-2007137874-A2 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH GALAPAGOS SAS (FR) 2007-12-06 WO disclosed
WO-2007137874-A2 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH GALAPAGOS SAS (FR) 2007-12-06 WO disclosed
EP-0160241-B1 PROCESS FOR PRODUCING AN ALPHA-AROMATIC GROUP SUBSTITUTED ALKANOIC ACID DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 1988-11-30 EP disclosed
US-4649213-A DIALKOXYALCOHOL, REARRANGEMENTS, BASE OR AMIDE, HALO-SULFUR COMPOUND KYOWA HAKKO KOGYO CO. LTD. (JP) 1987-03-10 US disclosed
EP-0160241-A1 Process for producing an alpha-aromatic group substituted alkanoic acid derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 1985-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH NR5A1, AR, HSD17B7 LMNA 4085/4885HPGD 844/4885ELANE 3548/4885
US-20100063120-A1 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such NR5A1, AR, HSD17B7 LMNA 4071/4885HPGD 817/4885ELANE 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.